ImmunoGen Inc.
Find Ratings ReportsIMMUNOGEN INC's gross profit margin for the third quarter of its fiscal year 2023 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth. IMMUNOGEN INC is extremely liquid. Currently, the Quick Ratio is 5.52 which clearly shows the ability to cover any short-term cash needs. IMGN managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 215.49% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY23 | Q3 FY22 |
---|---|---|
Net Sales ($mil) | 113.43 | 15.38 |
EBITDA ($mil) | 26.38 | -77.01 |
EBIT ($mil) | 25.96 | -77.43 |
Net Income ($mil) | 30.75 | -77.76 |
Balance Sheet | Q3 FY23 | Q3 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 605.54 | 309.51 |
Total Assets ($mil) | 822.1 | 358.8 |
Total Debt ($mil) | 110.22 | 50.75 |
Equity ($mil) | 561.6 | 178.01 |
Profitability | Q3 FY23 | Q3 FY22 |
---|---|---|
Gross Profit Margin | 23.26 | -500.85 |
EBITDA Margin | 23.25 | -500.84 |
Operating Margin | 22.88 | -503.6 |
Sales Turnover | 0.35 | 0.27 |
Return on Assets | -8.94 | -56.04 |
Return on Equity | -13.09 | -112.97 |
Debt | Q3 FY23 | Q3 FY22 |
---|---|---|
Current Ratio | 5.7 | 3.19 |
Debt/Capital | 0.16 | 0.22 |
Interest Expense | 3.59 | 0.87 |
Interest Coverage | 7.22 | -89.31 |
Share Data | Q3 FY23 | Q3 FY22 |
---|---|---|
Shares outstanding (mil) | 265.84 | 220.75 |
Div / share | 0.0 | 0.0 |
EPS | 0.1 | -0.31 |
Book value / share | 2.11 | 0.81 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 8183705.0 | 4539241.0 |
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 14.78 indicates a significant premium versus the S&P 500 average of 4.54 and a significant discount versus the subsector average of 16.42. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, IMMUNOGEN INC proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IMGN NM | Peers 94.35 | IMGN NM | Peers 53.83 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. IMGN's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. IMGN's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
IMGN 80.08 | Peers 18.17 | IMGN NA | Peers 1.95 | |||||||||||||||||||||
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. IMGN is trading at a significant premium to its peers. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
IMGN 14.78 | Peers 16.42 | IMGN 62.20 | Peers -2.59 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. IMGN is trading at a discount to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. IMGN is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
IMGN 28.87 | Peers 64.15 | IMGN 200.82 | Peers 30.79 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. IMGN is trading at a significant discount to its subsector on this measurement. |
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share. IMGN has a sales growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||